Aditxt, Inc. announced on December 11, 2023, that it entered a merger agreement with Evofem Biosciences, with a follow-up financial amendment filed on May 19, 2025, detailing pro forma financial statements as of March 31, 2025. This merger aims to enhance Aditxt's strategic growth and may involve a $1.5 million investment from Aditxt to Evofem.